Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study.
Lai S, Mangiulli M, Perrotta AM, Gigante A, Napoleoni L, Cipolloni E, Mitterhofer AP, Gasperini ML, Muscaritoli M, Cianci R, Giovannetti A, Falco F, Mastroluca D, Mazzaferro S.
Lai S, et al. Among authors: napoleoni l.
Curr Vasc Pharmacol. 2021;19(5):556-564. doi: 10.2174/1570161118999200918094809.
Curr Vasc Pharmacol. 2021.
PMID: 32957887